TRACON Pharmaceuticals Inc (TCON) Expected to Post Earnings of -$0.27 Per Share

Share on StockTwits

Analysts predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post ($0.27) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for TRACON Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.19). TRACON Pharmaceuticals posted earnings per share of $0.07 in the same quarter last year, which would indicate a negative year over year growth rate of 485.7%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that TRACON Pharmaceuticals will report full-year earnings of ($1.23) per share for the current financial year, with EPS estimates ranging from ($1.38) to ($1.08). For the next fiscal year, analysts forecast that the business will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.42) to ($0.27). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover TRACON Pharmaceuticals.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.02).

TCON has been the topic of several recent analyst reports. Needham & Company LLC dropped their price objective on TRACON Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 10th. ValuEngine upgraded TRACON Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Finally, Zacks Investment Research upgraded TRACON Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, August 14th.

NASDAQ:TCON traded up $0.02 during trading hours on Wednesday, hitting $2.12. 58,000 shares of the company traded hands, compared to its average volume of 159,508. The company has a current ratio of 4.84, a quick ratio of 4.84 and a debt-to-equity ratio of 0.17. TRACON Pharmaceuticals has a one year low of $1.90 and a one year high of $3.95. The stock has a market cap of $62.66 million, a PE ratio of -1.89 and a beta of 1.88.

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its stake in TRACON Pharmaceuticals by 368.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 76,999 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 60,574 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in shares of TRACON Pharmaceuticals during the 1st quarter worth $213,000. Renaissance Technologies LLC raised its stake in shares of TRACON Pharmaceuticals by 73.0% during the 4th quarter. Renaissance Technologies LLC now owns 264,700 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 111,700 shares during the period. Finally, NEA Management Company LLC raised its stake in shares of TRACON Pharmaceuticals by 25.7% during the 1st quarter. NEA Management Company LLC now owns 3,467,181 shares of the biopharmaceutical company’s stock worth $7,975,000 after purchasing an additional 707,964 shares during the period. Institutional investors and hedge funds own 56.40% of the company’s stock.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD.

Featured Article: How Do Tariffs Affect Trade Balances?

Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply